Back to top
more

Akebia Therapeutics (AKBA)

(Delayed Data from NSDQ)

$1.43 USD

1.43
2,524,000

+0.05 (3.62%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $1.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for AKBA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Akebia Therapeutics, Inc. [AKBA]

Reports for Purchase

Showing records 1 - 20 ( 99 total )

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

02/27/2026

Company Report

Pages: 7

Dialysis Organization Growth and Deepening VAFSEO's Reach; Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

02/06/2026

Company Report

Pages: 8

Focusing on VAFSEO with Praliciguat, AKB-097 and Pipeline Upside-Model Updates, Reit Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

12/02/2025

Daily Note

Pages: 5

Kidney Disease Pipeline Expansion Beyond VAFSEO, With AKB-097 and Praliciguat; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

11/11/2025

Company Report

Pages: 7

VAFSEO Expansion Can Fuel Near-Term Growth in Dialysis Market; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

10/30/2025

Company Report

Pages: 7

VAFSEO Dialysis Opportunity Just Starting; Shift From Non-Dialysis Path; PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

08/08/2025

Company Report

Pages: 7

Positioning of VAFSEO for 2H25 Dialysis Organization Expansion; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

06/04/2025

Company Report

Pages: 12

Assuming Coverage with Buy Rating and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CAUFIELD M

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

05/29/2025

Industry Report

Pages: 34

HCW 2025 Bioconnect @ Nasdaq Investor Conference Takeaways

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 75.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

04/04/2025

Company Report

Pages: 8

XOANACYL Moves Closer to EC Approval With Positive CHMP Opinion

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

03/14/2025

Company Report

Pages: 8

4Q Recap; Strong Vafseo Launch Right Out of the Gate and Gaining Momentum

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

01/23/2025

Daily Note

Pages: 3

NICE Recommends Vafseo''s Use As a Replacement for ESAs in CKD Patients on Dialysis in the UK

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

01/22/2025

Industry Report

Pages: 74

Innovation, Optimism, and Opportunity: Critical Themes for Biotech Investors

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 150.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

01/14/2025

Company Report

Pages: 8

New Contracts Offer Vafseo to Nearly All U.S. Dialysis Patients; Vafseo Non-Dialysis CVOT Begins in Mid-2025; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

10/23/2024

Daily Note

Pages: 3

We View New Vafseo Supply Contract With DO Serving 200,000 U.S. Patients as a Significant Achievement

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

10/10/2024

Daily Note

Pages: 3

Vafseo TDAPA Reimbursement Begins on January 1, 2025; Our Focus Turns to Supply Agreements With DOs; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

10/08/2024

Daily Note

Pages: 3

Akebia Signs Vafseo Commercial Supply Contract With USRC

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

09/06/2024

Daily Note

Pages: 4

VOICE Investigator-Initiated Outcomes Trial Could Support Vafseo TIW Dosing to Match Dialysis Scheduling; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

08/12/2024

Company Report

Pages: 8

2Q Recap: Vafseo Market Launch Set for January 2025 Under TDAPA; WAC Price Optimizes Value to Access; Raise PT to $7.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

03/28/2024

Company Report

Pages: 6

FDA Approves Vafseo For Anemia in CKD on Dialysis; Akebia to Launch Vafseo in January 2025; Raise PT to $6.00

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Akebia Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

03/15/2024

Company Report

Pages: 8

4Q Recap; We Anticipate Vadadustat''s U.S. Approval By March 27 PDUFA Date

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party